The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
Alice Mogenet, Laurent Greillier, Pascale Tomasini Aix Marseille University, CNRS, INSERM, CRCM, APHM, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, FranceCorrespondence: Pascale TomasiniService d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Hôpi...
Saved in:
Main Authors: | Mogenet A (Author), Greillier L (Author), Tomasini P (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
by: Sophie Marolleau, et al.
Published: (2023) -
Prognostic value of activin A level in patients with advanced lung cancer and sarcopenia
by: V. V. Kechedzhyiev
Published: (2024) -
Barriers, Facilitators, and Suggested Interventions for Lung Cancer Screening Among a Rural Screening-Eligible Population
by: Jenna E. Schiffelbein, et al.
Published: (2020) -
HUNCHEST projects-advancing low-dose CT lung cancer screening in Hungary
by: Anna Kerpel-Fronius, et al.
Published: (2024) -
Personalized Medicine in the Field of Inflammatory Skin Disorders
Published: (2022)